News & Perspective

Oct 27, 2014

Oct 27, 2014

CSL-Novartis deal includes US cell-based flu vaccine plant

The $275 million deal will make the company the second leading player in the $4 billion global flu vaccine market.

Jan 11, 2010

Jan 11, 2010

US reduces order for CSL's H1N1 vaccine

(CIDRAP News) – The US government recently cut back its contract for H1N1 influenza vaccine from Australian-based CSL Biotherapies by about 60%, mainly as a result of delays related to the company's commitment to make vaccine for Australia first.

Nov 18, 2009

Nov 18, 2009

House committees probe pandemic vaccine decisions

(CIDRAP News) – Federal officials, along with representatives from four vaccine companies, appeared before two US House of Representatives committees today to answer questions about why the nation hasn't stretched scarce pandemic vaccine supply with adjuvants and if a more federally directed distribution system might help vaccine get to more high-risk patients.

Sep 10, 2009

Sep 10, 2009

Early results suggest 1 dose of H1N1 vaccine may be protective

(CIDRAP News) – Preliminary clinical trial results suggest that pandemic H1N1 vaccines made by Novartis and CSL Ltd. will provide protection in adults with just one dose, raising hope for a less difficult immunization program than has been anticipated.

Aug 18, 2009

Aug 18, 2009

FDA clears CSL's vaccine-finishing facility in US

(CIDRAP News) – The US Food and Drug Administration (FDA) today approved a vaccine filling and packaging facility in Illinois owned by CSL Biotherapies, one of the five companies under contract to make novel H1N1 vaccines for the United States, the company announced.

Aug 14, 2009

Aug 14, 2009

Officials lower expectations for size of first novel flu vaccine deliveries

(CIDRAP News) – Federal officials today during a pandemic H1N1 planning update dialed back the number of novel flu vaccine doses they expect in October from 120 million to 45 million, listing several reasons for the smaller projection.

Jan 23, 2008

Jan 23, 2008

GAO cites barriers to antiviral, vaccine roles in pandemic

(CIDRAP News) – Antiviral medications and vaccines are two tools that many government and health officials hope will stall the spread of an influenza pandemic, but each strategy has daunting challenges, according to a new report from Congress's Government Accountability Office (GAO).

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»